Viridian Therapeutics Inc...
(VRDN)
undefined
undefined%
At close: undefined
Company Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases.
It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.
Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Viridian Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 94 |
| CEO | Stephen F. Mahoney J.D., MBA |
Contact Details
Address: 221 Crescent Street Waltham, Massachusetts United States | |
| Website | https://www.viridiantherapeutics.com |
Stock Details
| Ticker Symbol | VRDN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590750 |
| CUSIP Number | 92790C104 |
| ISIN Number | US92790C1045 |
| Employer ID | 47-1187261 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Stephen F. Mahoney J.D., MBA | Chief Executive Officer, President & Director |
| Jennifer Tousignant J.D. | Chief Legal Officer |
| Thomas W. Beetham J.D., MBA | Chief Operating Officer |
| Dr. Eric N. Olson Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Marvin H. Caruthers Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder & Member of the Scientific Advisory Board |
| John A. Jordan | Vice President of Investor Relations & Corporate Communications |
| Melissa Manno | Chief Human Resources Officer |
| Seth Harmon | Senior Vice President of Finance and Accounting, Principal Financial & Accounting Officer |
| Vahe Bedian Ph.D. | Co-Founder & Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 30, 2024 | 4 | Filing |
| Sep 30, 2024 | 4 | Filing |